USPTO serial 97315865
TORQUE
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- FLORES, SHAKEYLA NO MIDDLE NAME
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with TORQUE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Westlake Village, CA, US
Westlake Village, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Holly Pranger
Holly Pranger PRANGER LAW PC88 GUY PLACE, SUITE 405SAN FRANCISCO, CA 94105United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in gene therapy; biological preparations for use in gene therapy; biological and pharmaceutical preparations, both comprised of therapeutic nucleic acids, namely, RNA, for the treatment and prevention of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmaceutical preparations for treating metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders | ACTIVE | — |
| 042 | Testing, inspection, research, and development of pharmaceutical preparations and biological preparations for gene therapy; Pharmaceutical research and development in the field of gene therapy; Biological research and development in the field of gene therapy; consulting services in the fields of biotechnology, pharmaceutical research and development, and in the field of genetic science; custom design and development of biochemical reagents, namely, for use in the synthesis for others of clinical medical reagents for use in gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the fields of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, medical and agriculture fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and development of gene therapy delivery through use of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of genetic diseases and disorders, genomic diseases and disorders, neurological diseases and disorders, cardiological diseases and disorders, musculoskeletal diseases and disorders, cancer, infectious diseases, and immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; medical research services, namely, scientific research in the fields of genetic engineering and gene therapy services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 15, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 10, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 9, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 9, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 1, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 30, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 30, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 30, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 7, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 26, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 26, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 20, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 31, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 17, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 15, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 2, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 2, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 2, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 27, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 27, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 30, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 19, 2022 | NWAP | NEW APPLICATION ENTERED | — |